Kornimate/medical-research-clean huggingface dataset:
evaluation of c13 breath test for upper gastrointestinal bleeding in patients who need double antiplatelet after pci

Conditions: Acute Myocardial Infarction

Summary: hp infection is closely related to upper gastrointestinal bleeding in patients who need dual-antiplatelet after pci. taking anti-hp treatment has the effect of reducing bleeding risk. thus, we propose a scientific hypothesis: the c13 breath test may be used to assess the risk of upper gastrointestinal bleeding in patients who need dual- antiplatelet after pci.

our study is to retrospectively analyze the clinical data of 1606 patients of acute myocardial infarction who need dual- antiplatelet after pci.the diagnostic criteria for upper gastrointestinal bleeding is: 1.symptoms: digestive discomfort, such as abdominal pain, nausea, belching, acid reflux, etc.;2.mainly based on endoscopy examination, endoscopic examination showed that the stomach or duodenum showed spotted, linear or diffuse bleeding;3.the fecal examination:melena, tar-like stool, hematemesis, fecal occult blood, etc.the study was divided into two groups according to whether the c13 breath test was performed, and the c13 breath test component was the positive anti-hp treatment group and the non-anti-hp treatment group.and then compare the upper gastrointestinal bleeding rates of the above groups.

Eligibility criteria:
inclusion criteria: * the diagnosis of patients with coronary heart disease is based on the diagnostic criteria of aca/aha,the diagnostic criteria for upper gastrointestinal bleeding refer to the guidelines for the diagnosis and treatment of acute non-variceal upper gastrointestinal bleeding. * in the hospital, all patientsi were treated with clopidogrel 300 mg or ticagrelor 180 mg before surgery, and c13 breath test was performed after surgery. * all patients were treated with dual- antiplatelet. * the clinical data of the included subjects were complete. exclusion criteria: * patients with previous liver and kidney disease, cr greater than 150 μmol / l, ast or alt increased more than 2 times the normal value of patients. * patient with history of cerebrovascular disease. * patients with active gastrointestinal bleeding disease due to cirrhosis or other reasons before pci. * patients with abnormal coagulation. * diabetic patients, diagnostic criteria for anemia: 8th edition of internal medicine, adult males with hb less than 120g / l or rbc less than 4 × 10\^12 / l, adult women with hb less than 105g / l or rbc than 3.5 × 10\^12 / l. * patients with incomplete medical records;7.patient with pregnant. * patients with malignant tumors
impact of the preparation method of red cell concentrates on transfusion indices in thalassemic patients

Conditions: Thalassemia Major

Summary: this study compares the effects of packed red blood cells (prbcs) prepared in two different ways on the transfusion indices in beta(ß)-thalassemia transfusion-dependent patients. the two blood components types derive from the whole blood. in one case, the whole blood is leukoreduced with subsequent plasma removal. in the other case, plasma, buffy coat, and red blood cells (rbcs) are first separated and subsequently, the rbcs leukoreduced. each type of blood components will be subsequently given to one-half of the patients for a 6-month period and to the other half for other 6-month at the randomization phase, for a total of 12 months of crossed-treatment per patient.

at day hospital talassemia ed emoglobinopatie of ferrara, two different prbcs are available. the two types of blood components are obtained from whole blood, pre-storage leukoreduced and suspended in saline-adenine-glucose-mannitol (sagm). one method of preparation consists of the whole blood leukoreduction with subsequent plasma removal. the other method first separates plasma, buffy coat, and rbcs, and then the rbcs are leukoreduced. the two methods mainly differ in the final haemoglobin (hb) content: the hb level is lower (-13%, approximately) in the second method that also shows the advantage to produce platelets from the buffy coat. a prbcs unit is not as strictly defined as a therapeutic medication dose (pill or vial): individual prbcs units may substantially differ in their hb content, much more than the average difference between the two types of preparations. the aim of this study is to document the extent of the average difference between the two types of preparations, and its impacts on the transfusion indices of ß-thalassaemia transfusion-dependent patients. all patients will receive each blood component for a period of 6 months (crossover design), for a total of 12 months of transfusion treatment per patient.

Eligibility criteria:
inclusion criteria: * patient with beta(ß)-thalassaemia transfusion-dependent (ß-thalassemia major or ß-thalassemia intermedia transfusion-dependent, regularly transfused since at least 5 years exclusion criteria: * patient not exclusively transfused at day hospital thalassaemia and haemoglobinopathies of ferrara * patient with haemolytic auto-antibodies * patient transfused with washed packet rbcs units * severe splenomegaly (\>18 cm on echography) * elevated blood consumption (\>200 ml/kg of pure rbcs in the last year) * patient receiving haemoglobin inducers in the last 6 months * any significant clinical pulmonary, cardiovascular, endocrine, hepatic, gastrointestinal, renal, infectious, immunological including significant allo- or auto-immunisation disease, considered not adequately controlled prior to the study * patient treated with erythrocyte exchange * pregnant females

Keywords: packed rbcs leukodepletion buffy-coat transfusion
effects of dietary nitrate intake on cardiovascular performance in response to hand grip test in bodybuilders

Conditions: Steroid Abuse; Cardiovascular Abnormalities

Summary: through a randomized, crossover, double-blind, placebo-controlled clinical trial, 20 bodybuilders will participate a acute-day trial with two intervention protocols: 1) placebo and 2) nitrate; in which will ingest beet juice with or without no3 in its composition with a 7-day washout interval.


Eligibility criteria:
inclusion criteria: * anabolic steroid use in the past or actually; * participation at least one bodybuilding competition; exclusion criteria: * previous history of acute myocardial infarction and/or stroke; * allergy or intolerance to nitrate, gluten, or milk; * medications (proton pump inhibitors, beta-blockers, calcium channels antagonists).
the effect of negatively fluid balancing speed for icu patients with acute respiratory distress syndrome

Conditions: Fluid Loss

Summary: previous studies have shown that a positive fluid balance was an independent factor of worse prognosis in icu patients with acute respiratory distress syndrome (ards), and negative fluid balance has been demonstrated to increase oxygenation index, reduce time under mechanical ventilation and icu length of stay with no noticeable adverse effects. but there is no evidence that faster speed of negative fluid balance would be more beneficial for ards patients. so researchers designed the study to prove the effect of negatively fluid balancing speed for icu patients with ards.


Eligibility criteria:
inclusion criteria: ·patients with ards (berlin 2012 criterion） exclusion criteria: * pregnant women * unstable hemodynamics status * \< 18 years old
the utilization of a shoe insert on individuals with unilateral greater trochanteric pain syndrome on single leg stance, biomechanics, and pain intensity

Conditions: Gluteus Medius Muscle Strength; Lateral Hip Pain; Greater Trochanter Pain Syndrome, Gluteus Medius Tendinopathy, Gluteus Minimus Tendinopathy

Summary: we hypothesize that the addition of a unilateral neutral shoe insert combined with standard physical therapy (pt+si) will have greater improvements in pain and function at 12 weeks and 6 months compared to physical therapy with sham inserts (pt+sham) and physical therapy (pt) alone. in addition, we hypothesize that the addition of a neutral shoe insert in the involved limb will immediately improve biomechanics and pain with the single-leg stance test.


Eligibility criteria:
inclusion criteria: * subjects with a history of unilateral hip pain lasting more than three months. * subjects with a vas pain score of at least 3/10 localized to the lateral hip. * subjects with pain with palpation to lateral hip. * subjects with pain with either resisted hip abduction in relative adduction testing position and/or single leg stance test exclusion criteria: * subjects wearing custom foot orthoses at the time of recruitment. * subjects who endorse current low back pain ≥ 3 on the nrs or lumbar radiculopathy * subjects with a medical history of spinal or lower limb surgery in the past 6 months. * subjects with a medical history of total joint replacement of hip, knee, or ankle on the symptomatic side * subjects who have had a corticosteroid injection at the hip within the last 12 months; * subjects demonstrating clinical signs and symptoms of intra-articular hip joint pathology with ≥ 3/10 groin pain including imaging confirmed significant labral tearing requiring surgery or osteoarthritis \> 2 (mild) on kellgren-lawrence score on radiographs. * subjects previously diagnosed with systemic inflammatory conditions; active cancer/malignant tumors; or neurological conditions that would affect gait * subjects who have had physical therapy within the past 3 months for hip pain * if subjects are unable to commit to 12 weeks of therapy with one supervised session weekly * subjects who have the intention to perform treatments outside of this study including, but not limited to, dry needling or acupuncture, extracorporeal shockwave, therapeutic ultrasound, a tenex procedure, medication injection therapies, platelet-rich plasma injections, stem cell injections, and surgery.

Keywords: gluteus medius tendinopathy gluteus minimum tendinopathy greater trochanteric pain syndrome
progressive structured simulation-based surgical training program (process) - open vascular surgery

Conditions: Vascular Diseases; Competency-Based Education; Simulation Training

Summary: a triple-arm, randomized, simple-blinded clinical trial will be conducted. a control sequence and an intervention sequence of three subgroups with different exposure levels to the simulation program are proposed. group 1: open abdominal aortic repair (aaor), group 2: vascular anastomosis (va) and aaor, and group 3: specific micro-surgical skills, va and aaor. surgical residents of general, vascular, or cardiovascular surgery programs will be included. sample size calculation resulted in 45 participants, 15 in each group. simple blinding will involve external evaluators. randomization will occur as a simple randomization.


Eligibility criteria:
inclusion criteria: * vascular surgery, cardiothoracic surgery, and general surgery residents. * over 18 years old. exclusion criteria: * serious illnesses, such as advanced cancer, decompensated cardiovascular diseases, or severe neurological disorders, could be exclusion criteria due to concerns about the participant's safety and ability to complete the study. * participants who have known allergies to components of the interventions or have experienced severe adverse reactions in the past will be excluded from the study. * any medical condition that could interfere with the participant's ability to complete assessments or follow study guidelines could be a reason for exclusion. this could include, for example, severe physical disabilities or illnesses requiring continuous hospitalization. * individuals who cannot provide valid informed consent due to cognitive issues, mental impairment, or legal incapacity will be excluded from the study. * individuals who have had prior exposure to structured simulation programs in vascular surgery will be excluded. previous familiarity with simulation could influence study outcomes, introducing a prior learning bias that could distort the assessment of the intervention's effectiveness.
a comparative clinical trial evaluating the effect and safety of tacrolimus versus hydrocortisone

Conditions: Dermatologic Disease

Summary: one of the most frequent skin conditions is atopic dermatitis (ad), characterized by its pruritic inflammation effect. where the prevalence of ad increased in the last three decades by two or three folds worldwide, especially in developed countries, ad is supposed to affect about 15% to 30% of children, and 2% to 10% of adults. this type of dermatitis is frequently linked to a family history of other atopic illnesses such as allergic rhinitis or asthma.


Eligibility criteria:
inclusion criteria: * male or female, 2-16 years old ad patients. exclusion criteria: * patients diagnosed with other skin disorders of serious type and who are taking systemic corticosteroids or anti-inflammatory medications.
collection of real-life measurement data for tena smartcare change indicator in subjects with urinary incontinence

Conditions: Urinary Incontinence

Summary: this study is an explorative, open, single-arm clinical investigation to collect real-life measurement data in order to assess the mathematical algorithms involved in tena smartcare change indicator.

the purpose of this exploratory clinical investigation is to evaluate safety and to collect real-life measurement data using the tena smartcare change indicator. the collected data will be used to assess the device related algorithms. these algorithms have been established and verified in a laboratory environment. however, due to possible differences in parameters, real-life measurement data are to be collected to aid in further product development.

Eligibility criteria:
inclusion criteria: 1. the subject is willing and able to provide informed consent and to participate in the clinical investigation. 2. the subject is ≥18 years of age. 3. the subject is diagnosed with urinary incontinence. 4. the subject is being cared for at tre stiftelser. exclusion criteria: 1. the subject has ≥ 4 fecal "incidences" per week. 2. the subject has severe absorbent product related skin problems, as judged by the investigator. 3. the subject is hyper sensitive related to allergic reaction to any of the included materials, as judged by the investigator. 4. the subject has ≥ 2 intermittent urinary catheters per day. 5. the subject has a pacemaker or an implantable cardioverter-defibrillator. 6. the subject removes the incontinence product. 7. the subject demonstrates responsive behavior towards sensors. 8. the subject has any other condition that may make participation in the clinical investigation inappropriate, as judged by investigator. 9. the subject is not cared for at tre stiftelser. 10. the subject is pregnant or lactating.
the use of vibrational methods of influencing the lungs to restore their functional state

Conditions: Respiratory Failure

Summary: there will be formed of groups for application of vibration methods on the lungs: the method of vibroacoustic lung massage using the "bark vibrolung" device; the method of oscillating pep therapy using acapella dh green; the method of hardware stimulation of cough with a mechanical insufflator-aspirator comfort cough plus (comfortable cough plus). as a control group, classical manual chest massage with percussion and verbal stimulation of cough against the background of chest compressions with a total duration of 15 minutes will be used

the patient signs an informed consent to participate in the study after 10-12 hours tracheal extubation and transfer of the patient to spontaneous respiration. the application of one or another method of influence is carried out by the method of random sampling (the envelope method). next, a session is conducted using one of the methods of vibrational respiratory therapy. we are exploring the gas composition of arterial blood is examined, spirometry, and the respiratory rate is measured after 20 minutes of the procedure. further, respiratory therapy sessions are repeated 3 times a day for three days

Eligibility criteria:
inclusion criteria: 1. age from 18 years to 80 years inclusive. 2. performed cardiac surgery in ic conditions. 3. the patient's consent to participate in this study. exclusion criteria: 1. lack of productive contact with the patient 2. any disorder in the central nervous system in the perioperative period (acute cerebrovascular accident, coma, posthypoxic encephalopathy), being on a ventilator. 3. unstable hemodynamics or hemodynamically significant rhythm disturbances 4. shocks of various etiologies 5. inability to provide respiratory protection, high risk of aspiration 6. refusal of the patient to participate in this study

Keywords: medical rehabilitation; oxygenation
role of anti-ige in severe childhood eczema

Conditions: Atopic Eczema; Atopic Dermatitis; Child

Summary: to evaluate the efficacy of anti-ige (omalizumab/xolair) in children with severe eczema.

to address the value of anti-ige in children with severe eczema.

Eligibility criteria:
inclusion criteria: 1. children between the ages of 4-19 years 2. severe eczema 3. raised spige or spt to at least 1 food allergen or 1 aeroallergen and/or 4. clinical impression that allergic exposures cause worsening eczema. 5. total ige level \>300 ku/l 6. clinically proven ige-mediated allergic disease. 7. written informed consent to participate. exclusion criteria: 1. inability to comply with 2-4 weekly injections and clinic visits 2. evidence of underlying immune compromise, autoimmune disease, immune complex mediated conditions. 3. uncontrolled infection or unstable eczema. 4. malignancy or a history of malignancy. 5. pre-existing hepatic or renal impairment 6. known cardiovascular or ischaemic cerebrovascular abnormality. 7. other serious or uncontrolled systemic disease. 8. pregnancy or lactation. 9. known history of hypersensitivity or anaphylaxis to anti-ige injections or its constituents. 10. insufficient understanding of the trial assessments. 11. participation in a ctimp in the previous 60 days or (if known) 4 half-lives of the relevant medication, whichever is the greater. 12. investigator feels that there is a good clinical reason why the child would be unsuitable.
fat biology, sleep disorders, and cardiovascular disease

Conditions: Sleep Disordered Breathing; Cardiovascular Disease

Summary: endothelial dysfunction, or abnormal functioning of the lining of blood vessels, appears to be a key process in the development of cardiovascular disease. endothelial dysfunction appears to be caused by both sleep disordered breathing and obesity. as endothelial dysfunction is among the first clinical marker that predicts future cardiovascular events, understanding molecular mechanisms leading to impairment of endothelial function is very important. endothelial function requires the proper functioning of endothelial nitric oxide synthase (enos). enos activity is tightly regulated by caveolin-1, a protein important in the formation of cellular structures called caveolae. low levels of caveolin-1 facilitate optimal nitric oxide synthesis in endothelial cells as caveolin-1 helps to spatially organize enos in close proximity to signaling proteins that are important for enos activation. in certain diseases however, the balance of caveolin-1 and enos can be disrupted resulting in impaired nitric oxide synthesis and leading to endothelial dysfunction. the investigators therefore seek to characterize levels of caveolin-1, and correlate this with the presence or absence of sleep disordered breathing, obesity, and cardiovascular disease. the current irb protocol covers the performance of fat biopsies on subjects who have recently completed a sleep study either in the center for sleep medicine or in our sleep laboratory and were found to have sleep disordered breathing or no sleep disordered breathing, subject with sleep disordered breathing who have been treated successfully with continuous positive airway pressure for 3-6 months, and subjects undergoing other studies in our lab who are obese or non-obese and subjects who have known cardiovascular disease and subjects without known cardiovascular disease.


Eligibility criteria:
lac of contraindication for fat biopsy, inability to provide informed consent.
ws®1442 in slightly overweight subjects

Conditions: Overweight

Summary: the purpose of this study is to test: 1. safety of 900 mg or 1800 mg of ws® 1442 per day in overweight subjects (bmi 25 to 29,9 kg/m²) 2. pharmacodynamic effect of ws® 1442 on endothelial function versus nordic walking training in overweight subjects

60 overweight subjects with a bmi of 25 to 29,9 kg/m2 are to be included. the safety of 900 mg/1800 mg per day ws® 1442 is determined by adverse events, laboratory parameters, vital signs as well as by a treadmill test at the beginning and the end of the study. endothelial function measured before and after two different training modalities is compared to that measured before and after intake of two different doses of ws® 1442.

Eligibility criteria:
inclusion criteria: * written informed consent * male and female subjects aged 45-75 years * untrained * bmi between 25 and 29,9 kg/m² * resting blood pressure in sitting position ≤ 140/90 mmhg * inconspicuous ergometry exclusion criteria: * pregnancy or breastfeeding * any other current medication * intake of other hawthorn preparation or dietary supplements with possible influence on the interpretation of study results * any known diseases * alcohol or drug abuse/addiction * nicotine abuse * any known hypersensitivity to any of the ingredients of the investigated drug * inability or inadequate ability to write or speak german * not-postmenopausal women: positive pregnancy test or unsafe contraception * any urinary test finding requiring diagnostic assessment or treatment * deformation of the 2nd to 5th finger of both hands preventing an adequate measurement of endothelial function

Keywords: (bmi 25-29,9 kg/m2)